Cilcare's CIL001 Targets Cochlear Synaptopathy — An American/French Collaboration

[Fra]

It seems like the issue with the viral vector has now been resolved.

Is there any published paper that details the resolution of the viral vector issue?

 

[Josh-mh]

I am very interested in how Cilcare will be testing for cochlear synaptopathy outside of speech-in-noise tests and ABRs. I believe they are working on a way to test for this alongside their regenerative therapies.

 

[LovableGamer]

Hey, I just wanted to ask if there have been any updates on when the trials are starting. I believe it should be soon. I really hope I can join because of my hearing loss and tinnitus. I am hoping they will begin those groups early next year. If anyone has any information, please let me know. Thank you!

 

[ploughna]

On the topic of drug delivery through the round window discussed earlier in this thread, this is pretty interesting:

Cilcare launches a groundbreaking 3D Bioprinting Project with human cells to advance therapies for hearing disorders - Cilcare

€40 million series A completed to accelerate development of innovative treatments for early hearing loss

www.cilcare.com

 

[LovableGamer]

On the topic of drug delivery through the round window discussed earlier in this thread, this is pretty interesting:

Cilcare launches a groundbreaking 3D Bioprinting Project with human cells to advance therapies for hearing disorders - Cilcare

€40 million series A completed to accelerate development of innovative treatments for early hearing loss

www.cilcare.com

Awesome find! I really hope this leads to faster and smoother progress in research and treatment.

 

[JJL]

I have been in contact with the researcher; however, I'm a little reluctant. Intratympanic injections are no longer seen as the best route to the cochlea. All trials using this method have failed, with companies often blaming the lack of permeability.

Many institutions are now moving away from this approach and have discovered new proprietary routes.

Hi @Nick47, what are the new proprietary routes to get access to the cochlea?